Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation transactions.
Specific transaction details include:
- Reinvestment Prices (June 28, 2013): Notional dividends were re-invested at an average price of 1,404.56 pence per Ordinary Share and $44.5889 per ADS for 2011 Plan awards. For 2012 Plan awards, the average price was 1,448.10 pence per Ordinary Share and $45.9620 per ADS.
- Share Acquisitions: Various executives acquired Ordinary Shares and American Depositary Shares (ADSs) through personal contributions and company matching elements of the Plan.
Material Changes
The filing notes a reconciliation of notional dividends for 2011 and 2012 Plan awards. This adjustment reflects a change in Plan administration to ensure the originally intended number of notional dividends accrues over the relevant vesting period. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification regarding Rule 12g3-2(b) and Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the impact of the Plan administration change on future executive compensation accruals.
- Confirm the vesting schedules for the 2011 and 2012 Plan awards mentioned in the reconciliation.
- Review the full annual report (Form 20-F) for comprehensive financial metrics, as this 6-K contains only transaction notifications.